Kwan Sik Lee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4154110/publications.pdf

Version: 2024-02-01

110	4,128	32	61
papers	citations	h-index	g-index
117 all docs	117 docs citations	117 times ranked	5530 citing authors

#	Article	IF	CITATIONS
1	Anti-HBc IgG Levels: A Predictor of HBsAg Seroclearance in Chronic Hepatitis B Patients with Nucleos(t)ide Analogue-Induced HBeAg Seroclearance. Digestive Diseases and Sciences, 2022, 67, 321-328.	2.3	5
2	Long-term survival after CCRT and HAIC followed by ALPPS for hepatocellular carcinoma with portal vein invasion: a case report. Journal of Liver Cancer, 2022, 22, 84-90.	1.1	1
3	MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups. Digestive Diseases and Sciences, 2022, 67, 4919-4928.	2.3	26
4	Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial. Clinical and Molecular Hepatology, 2021, 27, 346-359.	8.9	10
5	Risk assessment of hepatocellular carcinoma and liverâ€related events using ultrasonography and transient elastography in patients with chronic hepatitis B. Journal of Viral Hepatitis, 2021, 28, 1362-1372.	2.0	4
6	Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B. European Journal of Gastroenterology and Hepatology, 2021, 33, 885-893.	1.6	4
7	Effects of Statin Use on the Development and Progression of Nonalcoholic Fatty Liver Disease: A Nationwide Nested Case-Control Study. American Journal of Gastroenterology, 2021, 116, 116-124.	0.4	63
8	Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial. American Journal of Gastroenterology, 2020, 115, 1217-1225.	0.4	16
9	Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immuneâ€tolerant phase. Alimentary Pharmacology and Therapeutics, 2020, 52, 196-204.	3.7	43
10	Phase I Radiation Dose-Escalation Study to Investigate the Dose-Limiting Toxicity of Concurrent Intra-Arterial Chemotherapy for Unresectable Hepatocellular Carcinoma. Cancers, 2020, 12, 1612.	3.7	4
11	Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance. BMC Gastroenterology, 2020, 20, 113.	2.0	7
12	Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation. Cancer Medicine, 2019, 8, 5023-5032.	2.8	25
13	Follow-Up Liver Stiffness Measurements after Liver Resection Influence Oncologic Outcomes of Hepatitis-B-Associated Hepatocellular Carcinoma with Liver Cirrhosis. Cancers, 2019, 11, 425.	3.7	8
14	Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection. Clinical Gastroenterology and Hepatology, 2019, 17, 1850-1859.e4.	4.4	45
15	Aromatase Inhibitors and Newly Developed Nonalcoholic Fatty Liver Disease in Postmenopausal Patients with Early Breast Cancer: A Propensity Score-Matched Cohort Study. Oncologist, 2019, 24, e653-e661.	3.7	16
16	Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis. World Journal of Gastroenterology, 2019, 25, 4959-4969.	3.3	13
17	Antiviral Therapy in Patients With Chronic Hepatitis C-related Hepatocellular Carcinoma Responding to Palliative Treatment. Journal of Clinical Gastroenterology, 2018, 52, 557-562.	2.2	6
18	Selective deletion of hepatocyte platelet-derived growth factor receptor \hat{l}_{\pm} and development of liver fibrosis in mice. Cell Communication and Signaling, 2018, 16, 93.	6.5	17

#	Article	IF	Citations
19	Motion effects on the measurement of stiffness on ultrasound shear wave elastography: a moving liver fibrosis phantom study. Medical Ultrasonography, 2018, 1, 14.	0.8	8
20	Long-Term Follow-Up of Patients after Autologous Bone Marrow Cell Infusion for Decompensated Liver Cirrhosis. Cell Transplantation, 2017, 26, 1059-1066.	2.5	15
21	Validation of risk prediction models for the development of HBV-related HCC: a retrospective multi-center 10-year follow-up cohort study. Oncotarget, 2017, 8, 113213-113224.	1.8	24
22	Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study. Radiation Oncology, 2017, 12, 133.	2.7	2
23	Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of DaclatasvirÂ+ÂAsunaprevir therapy in Korean patients with genotype 1b hepatitis C. Virology Journal, 2017, 14, 164.	3.4	5
24	Platelet-derived growth factor receptor $\hat{l}\pm$ in hepatocellular carcinoma is a prognostic marker independent of underlying liver cirrhosis. Oncotarget, 2017, 8, 39534-39546.	1.8	16
25	Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B. Clinical and Molecular Hepatology, 2017, 23, 331-339.	8.9	11
26	Suppression of PPARÎ ³ -mediated monoacylglycerol O-acyltransferase 1 expression ameliorates alcoholic hepatic steatosis. Scientific Reports, 2016, 6, 29352.	3.3	26
27	A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-na $\tilde{\mathbb{A}}$ -ve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus. Hepatology International, 2016, 10, 947-955.	4.2	17
28	A single adenovirus-mediated relaxin delivery attenuates established liver fibrosis in rats. Journal of Gene Medicine, 2016, 18, 16-26.	2.8	9
29	Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: Results from a multicentre study. Journal of Hepatology, 2015, 62, 526-532.	3.7	46
30	Accuracy of transient elastography in assessing liver fibrosis in chronic viral hepatitis: A multicentre, retrospective study. Liver International, 2015, 35, 2246-2255.	3.9	66
31	Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncology, The, 2015, 16, 1344-1354.	10.7	809
32	Usefulness of the Controlled Attenuation Parameter for Detecting Liver Steatosis in Health Checkup Examinees. Gut and Liver, 2015, 9, 405-10.	2.9	10
33	Assessment of Hepatic Fibrosis Regression by Transient Elastography in Patients with Chronic Hepatitis B Treated with Oral Antiviral Agents. Journal of Korean Medical Science, 2014, 29, 570.	2.5	15
34	Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice. Experimental and Molecular Medicine, 2014, 46, e127-e127.	7.7	23
35	Individual prediction model for lamivudine treatment response in hepatitis <scp>B</scp> virus e antigenâ€positive chronic hepatitis <scp>B</scp> patients. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1049-1055.	2.8	6
36	Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as firstâ€line therapy: A <scp>K</scp> orean multicenter study. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1463-1469.	2.8	26

#	Article	IF	Citations
37	Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut, 2014, 63, 996-1004.	12.1	67
38	Impact of postoperative hepatitis <scp>B</scp> virus reactivation in hepatocellular carcinoma patients who formerly had naturally suppressed virus. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1019-1027.	2.8	12
39	Entecavir plus adefovir versus adefovir plus lamivudine in hepatitis ⟨scp⟩B⟨/scp⟩ virus e antigenâ€positive, lamivudineâ€resistant chronic hepatitis ⟨scp⟩B⟨/scp⟩. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1485-1493.	2.8	4
40	Prognosis of hepatocellular carcinoma patients with extrahepatic metastasis and the controllability of intrahepatic lesions. Clinical and Experimental Metastasis, 2014, 31, 475-482.	3.3	26
41	Progression of diet induced nonalcoholic steatohepatitis is accompanied by increased expression of kruppel-like-factor 10 in mice. Journal of Translational Medicine, 2014, 12, 186.	4.4	22
42	STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC). Journal of Clinical Oncology, 2014, 32, 4006-4006.	1.6	38
43	Combined effects of an antioxidant and caspase inhibitor on the reversal of hepatic fibrosis in rats. Apoptosis: an International Journal on Programmed Cell Death, 2013, 18, 1481-1491.	4.9	12
44	Survival of Hepatocellular Carcinoma Patients May be Improved in Surveillance Interval not More Than 6 Months Compared With More Than 6 Months. Journal of Clinical Gastroenterology, 2013, 47, 538-544.	2.2	42
45	Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study. Clinical and Molecular Hepatology, 2013, 19, 165.	8.9	26
46	Quasispecies and Pre-Existing Drug-Resistant Mutations of Hepatitis B Virus in Patients with Chronic Hepatitis B. Gut and Liver, 2013, 7, 329-334.	2.9	12
47	Prediction of Esophageal Variceal Bleeding in B-Viral Liver Cirrhosis Using the P2/MS Noninvasive Index Based on Complete Blood Counts. Digestion, 2012, 86, 264-272.	2.3	2
48	Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels. European Journal of Gastroenterology and Hepatology, 2012, 24, 849-856.	1.6	35
49	CD11b ⁺ Gr1 ⁺ bone marrow cells ameliorate liver fibrosis by producing interleukin-10 in mice. Hepatology, 2012, 56, 1902-1912.	7.3	65
50	The significance of ICGâ€R15 in predicting hepatic toxicity in patients receiving radiotherapy for hepatocellular carcinoma. Liver International, 2012, 32, 1165-1171.	3.9	19
51	Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive, lamivudine-resistant chronic hepatitis B. Hepatology International, 2012, 6, 696-706.	4.2	7
52	Clinical characteristics of acute hepatitis A complicated by acute kidney injury. Scandinavian Journal of Infectious Diseases, 2012, 44, 144-148.	1.5	4
53	Transitional features of histologic type of nonâ€alcoholic fatty liver disease in Korean young men. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 142-148.	2.8	4
54	Antifibrotic effects of magnesium lithospermate B on hepatic stellate cells and thioacetamide-induced cirrhotic rats. Experimental and Molecular Medicine, 2011, 43, 341.	7.7	36

#	Article	IF	Citations
55	Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B. Antiviral Therapy, 2011, 16, 469-477.	1.0	20
56	The usefulness of liver stiffness measurement using FibroScan in chronic hepatitis C in South Korea: A multicenter, prospective study. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 171-178.	2.8	42
57	Risk Assessment of Esophageal Variceal Bleeding in B-Viral Liver Cirrhosis by a Liver Stiffness Measurement-Based Model. American Journal of Gastroenterology, 2011, 106, 1654-1662.	0.4	56
58	Autologous Bone Marrow Infusion Activates the Progenitor Cell Compartment in Patients with Advanced Liver Cirrhosis. Cell Transplantation, 2010, 19, 1237-1246.	2.5	84
59	How Can We Enhance the Performance of Liver Stiffness Measurement Using FibroScan in Diagnosing Liver Cirrhosis in Patients With Chronic Hepatitis B?. Journal of Clinical Gastroenterology, 2010, 44, 66-71.	2.2	94
60	Association Between Polymorphism of Tumor Necrosis Factor-α Promoter and Response to Lamivudine Treatment in Patients with Chronic Hepatitis B. Digestive Diseases and Sciences, 2010, 55, 2043-2048.	2.3	7
61	External Validation of P2/MS and Comparison with Other Simple Non-invasive Indices for Predicting Liver Fibrosis in HBV-Infected Patients. Digestive Diseases and Sciences, 2010, 55, 2636-2643.	2.3	7
62	Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology, 2010, 51, 415-421.	7.3	107
63	Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver International, 2010, 30, 546-553.	3.9	225
64	Prospective validation of P2/MS noninvasive index using complete blood counts for detecting oesophageal varices in B-viral cirrhosis. Liver International, 2010, 30, 860-866.	3.9	16
65	A novel liver stiffness measurement-based prediction model for cirrhosis in hepatitis B patients. Liver International, 2010, 30, 1073-1081.	3.9	31
66	Clinical Efficacy of a 24-months Course of Lamivudine Therapy in Patients with HBeAg Negative Chronic Hepatitis B: A Long-term Prospective Study. Journal of Korean Medical Science, 2010, 25, 882.	2.5	15
67	Autoimmune Thyroiditis during Antiviral Therapy with Peginterferon. Journal of Korean Endocrine Society, 2010, 25, 68.	0.1	0
68	A Liver Stiffness Measurement-Based, Noninvasive Prediction Model for High-Risk Esophageal Varices in B-Viral Liver Cirrhosis. American Journal of Gastroenterology, 2010, 105, 1382-1390.	0.4	194
69	Usefulness of FibroScan for Detection of Early Compensated Liver Cirrhosis in Chronic Hepatitis B. Digestive Diseases and Sciences, 2009, 54, 1758-1763.	2.3	122
70	Antiviral Therapy for Chronic Hepatitis B. Journal of the Korean Medical Association, 2009, 52, 831.	0.3	0
71	Rescue Monotherapy in Lamivudine-Resistant Hepatitis B e Antigen-Positive Chronic Hepatitis B: Adefovir versus Entecavir. Antiviral Therapy, 2009, 14, 705-712.	1.0	26
72	Clinical Course of Virologic Breakthrough after Emergence of YMDD Mutations in HBeAg-Positive Chronic Hepatitis B. Intervirology, 2008, 51, 293-298.	2.8	8

#	Article	IF	CITATIONS
73	Salvage Chemotherapy with Docetaxel and Epirubicin for Advanced/Metastatic Gastric Cancer. Oncology, 2007, 73, 2-8.	1.9	6
74	Clevudine Therapy for 24 Weeks Further Reduced Serum Hepatitis B Virus DNA Levels and Increased ALT Normalization Rates without Emergence of Viral Breakthrough than 12 Weeks of Clevudine Therapy. Intervirology, 2007, 50, 296-302.	2.8	17
75	Anti-hepatitis A virus seroprevalence among patients with chronic viral liver disease in Korea. European Journal of Gastroenterology and Hepatology, 2007, 19, 923-926.	1.6	16
76	PIVKA-II Is a Useful Tumor Marker for Recurrent Hepatocellular Carcinoma after Surgical Resection. Oncology, 2007, 72, 52-57.	1.9	91
77	Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology, 2007, 45, 1172-1178.	7.3	129
78	Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology, 2007, 46, 1041-1048.	7.3	112
79	Longâ€term outcome of chronic hepatitis B based on histological grade and stage. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 383-388.	2.8	79
80	A peroxisome-proliferator activated receptor- \hat{l}^3 ligand could regulate the expression of leptin receptor on human hepatic stellate cells. Histochemistry and Cell Biology, 2007, 127, 495-502.	1.7	18
81	Efficacy and Long-Term Follow Up of Combination Therapy with Interferon Alpha and Ribavirin for Chronic Hepatitis C in Korea. Yonsei Medical Journal, 2006, 47, 793.	2.2	6
82	Hepatic stellate cells primed with cytokines upregulate inflammation in response to peptidoglycan or lipoteichoic acid. Laboratory Investigation, 2006, 86, 676-686.	3.7	71
83	Association of genetic variations in CCR5 and its ligand, RANTES with clearance of hepatitis B virus in Korea. Journal of Medical Virology, 2006, 78, 1564-1571.	5.0	37
84	Long-term Clinical Outcome of Phase IIb Clinical Trial of Percutaneous Injection with Holmium-166/Chitosan Complex (Milican) for the Treatment of Small Hepatocellular Carcinoma. Clinical Cancer Research, 2006, 12, 543-548.	7.0	82
85	The Clinical Impact of Early Detection of the Ymdd Mutant on the Outcomes of Long-Term Lamivudine Therapy in Patients with Chronic Hepatitis B. Antiviral Therapy, 2006, 11 , 447-455.	1.0	31
86	Usefulness of urine strip test in the rapid diagnosis of spontaneous bacterial peritonitis. Liver International, 2005, 25, 1197-1201.	3.9	35
87	Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study. Yonsei Medical Journal, 2005, 46, 399.	2.2	109
88	Viral Hepatitis: Focus on Clinical Manifestations of Hepatitis A, B and C. Taehan Uihak Hyophoe Chi the Journal of the Korean Medical Association, 2005, 48, 428.	0.1	2
89	Hepatitis B virus infection after renal transplantation in the presence of antibody to hepatitis B surface antigen immunity. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, 847-853.	2.8	13
90	Pyloric Brunner's gland hamartoma. Gastrointestinal Endoscopy, 2004, 59, 76.	1.0	0

#	Article	IF	Citations
91	Apoptosis of hepatic stellate cells in carbon tetrachloride induced acute liver injury of the rat: analysis of isolated hepatic stellate cells. Journal of Hepatology, 2003, 39, 960-966.	3.7	32
92	Acute Cholecystitis at T2-weighted and Manganese–enhanced T1-weighted MR Cholangiography: Preliminary Study. Radiology, 2003, 227, 580-584.	7.3	55
93	Duodenal metastatic amelanotic melanoma. Gastrointestinal Endoscopy, 2003, 58, 101.	1.0	0
94	Emergence of YMDD motif mutant of hepatitis B virus during short-term lamivudine therapy in South Korea. Journal of Hepatology, 2001, 35, 92-98.	3.7	37
95	Lower gastrointestinal bleeding due to cytomegalovirus ileal ulcers in an immunocompetent man. Yonsei Medical Journal, 2001, 42, 147.	2.2	6
96	Oxidative stress effect on the activation of hepatic stellate cells. Yonsei Medical Journal, 2001, 42, 1.	2.2	48
97	Tissue plasminogen activator and plasminogen activator inhibitor-1 in human choledochal bile. Yonsei Medical Journal, 2000, 41, 119.	2.2	2
98	A case of minute intraductal papillary mucinous tumor of the pancreas presenting with recurrent acute pancreatitis. Yonsei Medical Journal, 2000, 41, 528.	2.2	9
99	Obstructive jaundice and acute cholangitis due to papillary stenosis. Yonsei Medical Journal, 1999, 40, 191.	2.2	3
100	Non-alcoholic duct-destructive chronic pancreatitis: recognition before definitive treatment. Yonsei Medical Journal, 1999, 40, 518.	2.2	7
101	Villous adenoma of the bile ducts: a case report and a review of the reported cases in Korea. Yonsei Medical Journal, 1999, 40, 84.	2.2	20
102	A case of paraesophageal hernia repaired by laparoscopic approach. Yonsei Medical Journal, 1996, 37, 151.	2.2	4
103	Spontaneous bowel perforation during the course of acute pancreatitis: a case report. Yonsei Medical Journal, 1996, 37, 158.	2.2	12
104	Peritoneoscopic liver biopsy findings in asymptomatic chronic HBsAg carriers with normal liver function tests and no hepatomegaly. Yonsei Medical Journal, 1996, 37, 295.	2.2	4
105	A case of flutamide-induced acute cholestatic hepatitis: a case report. Yonsei Medical Journal, 1996, 37, 225.	2.2	9
106	Anorectal dysfunction in systemic sclerosis. Journal of Korean Medical Science, 1996, 11, 244.	2.5	10
107	Case Report : Extrahepatic Bile Duct Hepatocellular Carcinoma without Primary Hepatic Parenchymal Lesions. Korean Journal of Internal Medicine, 1996, 11, 169-174.	1.7	16
108	Detection of Hepatocelluar Carcinoma in MR Arterial Portography; Diagnostic Significance as a Pre-Operative Evaluation. Journal of the Korean Radiological Society, 1996, 35, 365.	0.0	0

#	Article	IF	CITATIONS
109	A large common bile duct stone migrated from the gallbladder through a cholecystohepaticodochal fistula: an unusual complication of Mirizzi syndrome type II. Yonsei Medical Journal, 1995, 36, 206.	2.2	0
110	Dysphagia due to mediastinal tuberculous lymphadenitis presenting as an esophageal submucosal tumor: a case report. Yonsei Medical Journal, 1995, 36, 386.	2.2	10